TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06203756

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Omnibotics Robotic-assisted Total Knee Arthroplasty with Apex UC
Description: Robotic-assisted total knee arthroplasty in femur and tibial first workflows using the BalanceBot to characterize soft tissue balance, and the Apex UltraCongruent (UC) knee implant type

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Omnibotics Robotic-assisted Total Knee Arthroplasty with Apex UC
Description: Robotic-assisted total knee arthroplasty in femur and tibial first workflows using the BalanceBot to characterize soft tissue balance, and the Apex UltraCongruent (UC) knee implant type

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Omnibotics Robotic-assisted Total Knee Arthroplasty with Apex UC
Description: Robotic-assisted total knee arthroplasty in femur and tibial first workflows using the BalanceBot to characterize soft tissue balance, and the Apex UltraCongruent (UC) knee implant type

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Omnibotics Robotic-assisted Total Knee Arthroplasty with Apex UC
Description: Robotic-assisted total knee arthroplasty in femur and tibial first workflows using the BalanceBot to characterize soft tissue balance, and the Apex UltraCongruent (UC) knee implant type

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Omnibotics Robotic-assisted Total Knee Arthroplasty with Apex PS
Description: Robotic-assisted total knee arthroplasty with a tibial first workflow using the BalanceBot to characterize soft tissue balance, and the Apex PosteriorStabilized (PS) knee implant type

Intervention type: DEVICE
Group type: OTHER
Intervention: Omnibotics Robotic-assisted Total Knee Arthroplasty with Apex Revision
Description: Robotic-assisted total knee arthroplasty with a tibial first workflow using the BalanceBot to characterize soft tissue balance, and the Apex Revision knee implant type
Study: NCT01471535

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated interferon alfa-2a
Description: patients were given peginterferon alfa-2a (40KD) (Pegasys®; Roche, Basel, Switzerland)180 µg by subcutaneous injection once weekly for 120 weeks
Study: NCT00703365

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib and Gemcitabine
Description: Sorafenib 400 mg po bid daily and Gemcitabine IV 1,000 mg/m2 on day 1,8, 15 of a 28-day cycle (up to 6 cycles), then followed by Sorafenib 400 mg po bid daily maintenance until disease progression.
Study: NCT01469884

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: The conversion will be performed abruptly for all patients. Calcineurin inhibitor will be discontinued one day before the day of conversion (Day 1). Everolimus will be introduced on day 1 at dose of 3 mg/d (1,5mg bid), and then everolimus trough levels will be adjusted to achieve 6-10 ng/ml.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclosporine
Description: Trough level should be between 100 and 200ng/ml.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus
Description: Trough level should be between 5 and 10ng/ml.
Study: NCT03074968

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Benzydamine Hydrochloride
Description: Benzydamine Hydrochloride application

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: normal saline application
Study: NCT01823458

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lottery Insurance

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard Lottery
Study: NCT01895868

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Simulation-based ultrasound training
Study: NCT03540901

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ACETAZOLAMIDE oral capsule
Description: Administration of 125mg acetazolamide in the morning, 250mg in the evening, starting 24 hours before departure to 3100m

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Administration of equally looking placebo capsules in the morning and evening, starting 24 hours before departure to 3100m
Study: NCT03103529

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Active Rehabilitation

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Active Rehabilitation
Study: NCT02791139

Intervention type: OTHER
Intervention: Cardiovascular Magnetic Resonance Imaging (MRI)
Description: Cardiovascular MRI uses interaction of the magnetic properties of body tissues with strong magnetic fields to create heart images.

Intervention type: OTHER
Intervention: Cardiovascular Magnetic Resonance Imaging (MRI)
Description: Cardiovascular MRI uses interaction of the magnetic properties of body tissues with strong magnetic fields to create heart images.

Intervention type: OTHER
Intervention: Echocardiography
Description: To measure heart chamber size, heart function, blood vessel size and blood vessel function. These measurements will help us understand the type and severity of heart failure.

Intervention type: OTHER
Intervention: Echocardiography
Description: To measure heart chamber size, heart function, blood vessel size and blood vessel function. These measurements will help us understand the type and severity of heart failure.

Intervention type: OTHER
Intervention: Tonometry
Description: Tonometry is a noninvasive method to obtain arterial pressure waveform

Intervention type: OTHER
Intervention: Tonometry
Description: Tonometry is a noninvasive method to obtain arterial pressure waveform

Intervention type: OTHER
Intervention: Genetic Testing (Blood)
Description: The blood will be stored for genetic tests and development of cell lines to study genetic risks for aging related diseases and cardiovascular disease.

Intervention type: OTHER
Intervention: Genetic Testing (Blood)
Description: The blood will be stored for genetic tests and development of cell lines to study genetic risks for aging related diseases and cardiovascular disease.

Intervention type: OTHER
Intervention: Hand-Grip Strength Measurement
Description: We will measure your hand grip strength using a standard hand dynamometer which is a portable meter that you will use your hands to press on.

Intervention type: OTHER
Intervention: Body Fat Mass Analysis
Description: Body composition will be analysed by a body composition analyser machine onto which you will have to stand on.

Intervention type: OTHER
Intervention: Body Fat Mass Analysis
Description: Body composition will be analysed by a body composition analyser machine onto which you will have to stand on.
Study: NCT05939050

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Powered toothbrush
Description: Oral-B Powered toothbrush
Study: NCT04288440

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgery
Description: Removal of epiretinal membrane and ILM

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgery
Description: Removal of epiretinal membrane and ILM

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Vitrectomy machine
Description: Pars plana vitrectomy

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Vitrectomy machine
Description: Pars plana vitrectomy
Study: NCT02008539

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MSC_apceth_101
Study: NCT01154699

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bilevel PAP (4 weeks)
Description: Subjects will use bilevel PAP each night for 4 weeks. The pressure levels will be adjusted by the investigators to increase lung volumes during the night.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bilevel PAP (4 weeks)
Description: Subjects will use bilevel PAP each night for 4 weeks. The pressure levels will be adjusted by the investigators to increase lung volumes during the night.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual Care (4 weeks)
Description: Subjects will continue with their usual asthma care. Investigators will make no changes to their medications or other habits.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual Care (4 weeks)
Description: Subjects will continue with their usual asthma care. Investigators will make no changes to their medications or other habits.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Washout Period (4 weeks)
Description: Subjects will continue with their usual asthma care in between the Usual Care and Bilevel PAP periods. Investigators will make no changes to their medications or other habits.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Washout Period (4 weeks)
Description: Subjects will continue with their usual asthma care in between the Usual Care and Bilevel PAP periods. Investigators will make no changes to their medications or other habits.
Study: NCT01774903

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TTS-fentanyl
Description: TTS-fentanyl patches releasing drug at the rate of 12.5 microgram (µg) per hour for 3 days. The patches will be replaced every 3 days until 30 days.
Study: NCT03286959

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PCR with calcium hydroxide

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PCR with RMGIC

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PCR with direct composite
Study: NCT04946240

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Supervised (BRACE) Group
Description: Supervised (BRACE) protocol include static, dynamic and anticipatory balance exercises, chair rise, stair climbing and floor transfer comes under the category of resistance exercises. 6 minutes walk test, marching in space and cycling comes in aerobic. count reverse for 50 remember 5 words, 5 animals, repeat 5 words, spell forward and backwards and cont even numbers comes in cognitive exercises.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Balance Exercises Group
Description: The home plan included Balance and Resistance exercises of BRACE protocol were provided to the control group but that was not supervised. Control group participants were also same assessed as the S-BRACE group. Before giving the training plan for home, it was elaborated in detail. For the convenience of participants, the BRACE protocol was also translated into Urdu and was given in the printed form. The data were collected at baseline, after 3 weeks, 6, 9 and then after 12 weeks of training
Study: NCT03230279

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sacroiliac joint fusion
Description: Minimally invasive SIJ fusion will be performed under general anesthesia with fluoroscopy. Using SI-LOK®, Sacroiliac Joint Fixation System, Globus Medical Inc. (Audubon, PA), this procedure involve placement of 2 to 3 implants across the SIJ to achieve stabilization and arthrodesis.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sacroiliac joint radiofrequency ablation
Description: Sacroiliac joint radio frequency ablation will be performed using either conventional or cooled radiofrequency ablation techniques aimed at the S1-S3 lateral branches and the L5 dorsal ramus. The choice between conventional or cooled RFN will be determined by the provider expertise.
Study: NCT00000254

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: 40% Nitrous oxide
Description: Used as pain assay positive control

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 40% Nitrous oxide
Description: Used as pain assay positive control

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 40% Nitrous oxide
Description: Used as pain assay positive control

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 40% Nitrous oxide
Description: Used as pain assay positive control

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham comparator
Description: 0% isoflurane in oxygen

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.2% isoflurane

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.4% isoflurane

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.6% isoflurane
Study: NCT03466060

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Opti-Free : RevitaLens / Clear Care : RevitaLens
Description: Subjects between the ages of 18-69 will be randomized to 1 of 3 lenses. Solutions will be administered contralaterally with 1 test solution and 1 of 2 control solutions prior to the subjects' follow-up visits.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Opti-Free : RevitaLens / Clear Care : RevitaLens
Description: Subjects between the ages of 18-69 will be randomized to 1 of 3 lenses. Solutions will be administered contralaterally with 1 test solution and 1 of 2 control solutions prior to the subjects' follow-up visits.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Opti-Free : RevitaLens / Clear Care : RevitaLens
Description: Subjects between the ages of 18-69 will be randomized to 1 of 3 lenses. Solutions will be administered contralaterally with 1 test solution and 1 of 2 control solutions prior to the subjects' follow-up visits.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Opti-Free : RevitaLens / RevitaLens : Clear Care
Description: Subjects between the ages of 18-69 will be randomized to 1 of 3 lenses. Solutions will be administered contralaterally with 1 test solution and 1 of 2 control solutions prior to the subjects' follow-up visits.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Opti-Free : RevitaLens / RevitaLens : Clear Care
Description: Subjects between the ages of 18-69 will be randomized to 1 of 3 lenses. Solutions will be administered contralaterally with 1 test solution and 1 of 2 control solutions prior to the subjects' follow-up visits.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Opti-Free : RevitaLens / RevitaLens : Clear Care
Description: Subjects between the ages of 18-69 will be randomized to 1 of 3 lenses. Solutions will be administered contralaterally with 1 test solution and 1 of 2 control solutions prior to the subjects' follow-up visits.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Clear Care : RevitaLens/ Opti-Free : RevitaLens
Description: Subjects between the ages of 18-69 will be randomized to 1 of 3 lenses. Solutions will be administered contralaterally with 1 test solution and 1 of 2 control solutions prior to the subjects' follow-up visits.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Clear Care : RevitaLens/ Opti-Free : RevitaLens
Description: Subjects between the ages of 18-69 will be randomized to 1 of 3 lenses. Solutions will be administered contralaterally with 1 test solution and 1 of 2 control solutions prior to the subjects' follow-up visits.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Clear Care : RevitaLens/ Opti-Free : RevitaLens
Description: Subjects between the ages of 18-69 will be randomized to 1 of 3 lenses. Solutions will be administered contralaterally with 1 test solution and 1 of 2 control solutions prior to the subjects' follow-up visits.
Study: NCT02824055

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive placebo matched to RO5545965 capsules orally daily in any of the three intervention period.
Study: NCT04892004

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Symptom recognition
Description: The patient receives a leaflet, which includes information about HF, primary symptoms, awareness of its detection and the fluid management plan. It also receives a weight diary, which helps him/her recall weight fluctuation and contact the nurse or doctor to call for help in a previous stage and avoid hospitalisation. Patients have to explain what they understand by HF, on follow-ups contacts, which are the main symptoms, if they are experiencing any of them and which difficulties managing fluid restriction and weight control. The leading investigator validates the information and teaches back contents if required.
Study: NCT01690286

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-38518168 3 mg
Description: One oral daily dose of JNJ-38518168 3 mg for 25 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-38518168 30 mg
Description: One oral daily dose of JNJ-38518168 30 mg for 25 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-38518168 10 mg
Description: One oral daily dose of JNJ-38518168 10 mg for 25 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketoconazole 200 mg
Description: Oral doses of ketoconazole 200 mg every 12 hours, from Day 22 through Day 25.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketoconazole 200 mg
Description: Oral doses of ketoconazole 200 mg every 12 hours, from Day 22 through Day 25.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketoconazole 200 mg
Description: Oral doses of ketoconazole 200 mg every 12 hours, from Day 22 through Day 25.
Study: NCT03188549

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: AniosGel 85 NPC
Description: Hand hygiene formula
Study: NCT03466060

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Clear Care : RevitaLens / RevitaLens : Opti-Free
Description: Subjects between the ages of 18-69 will be randomized to 1 of 3 lenses. Solutions will be administered contralaterally with 1 test solution and 1 of 2 control solutions prior to the subjects' follow-up visits.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Clear Care : RevitaLens / RevitaLens : Opti-Free
Description: Subjects between the ages of 18-69 will be randomized to 1 of 3 lenses. Solutions will be administered contralaterally with 1 test solution and 1 of 2 control solutions prior to the subjects' follow-up visits.
Study: NCT02824055

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive placebo matched to RO5545965 capsules orally daily in any of the three intervention period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive placebo matched to RO5545965 capsules orally daily in any of the three intervention period.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: RO5545965
Description: Participants will receive RO5545965 5 mg capsules or RO5545965 15 mg capsules (5 mg for 3 days, 10 mg for 3 days and 15 mg for 15 days) orally daily in any of the three intervention period.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: RO5545965
Description: Participants will receive RO5545965 5 mg capsules or RO5545965 15 mg capsules (5 mg for 3 days, 10 mg for 3 days and 15 mg for 15 days) orally daily in any of the three intervention period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO5545965
Description: Participants will receive RO5545965 5 mg capsules or RO5545965 15 mg capsules (5 mg for 3 days, 10 mg for 3 days and 15 mg for 15 days) orally daily in any of the three intervention period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO5545965
Description: Participants will receive RO5545965 5 mg capsules or RO5545965 15 mg capsules (5 mg for 3 days, 10 mg for 3 days and 15 mg for 15 days) orally daily in any of the three intervention period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO5545965
Description: Participants will receive RO5545965 5 mg capsules or RO5545965 15 mg capsules (5 mg for 3 days, 10 mg for 3 days and 15 mg for 15 days) orally daily in any of the three intervention period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO5545965
Description: Participants will receive RO5545965 5 mg capsules or RO5545965 15 mg capsules (5 mg for 3 days, 10 mg for 3 days and 15 mg for 15 days) orally daily in any of the three intervention period.
Study: NCT02783495

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Device: iPad
Description: All patients will receive baseline neurocognitive and quality of life testing, followed by 3 months of the iPad-based intervention. At the end of the baseline visit, subjects will be lent an iPad to take home (or will be assisted in the installation of the ReMind app on their personal iPad) and instructed in the use of the ReMind app (and more basic iPad skills, if necessary). Subjects will review the intervention schedule (approximately 3 hours per week). Testing will be repeated 3 months after the baseline visit (i.e., immediately after the intervention) and 9 months after the baseline visit (i.e., 6 months after completion of the intervention), both time-points including a new MRI.
Study: NCT03466060

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Clear Care : RevitaLens / RevitaLens : Opti-Free
Description: Subjects between the ages of 18-69 will be randomized to 1 of 3 lenses. Solutions will be administered contralaterally with 1 test solution and 1 of 2 control solutions prior to the subjects' follow-up visits.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: RevitaLens : Clear Care/ Opti-Free : RevitaLens
Description: Subjects between the ages of 18-69 will be randomized to 1 of 3 lenses. Solutions will be administered contralaterally with 1 test solution and 1 of 2 control solutions prior to the subjects' follow-up visits.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: RevitaLens : Clear Care/ Opti-Free : RevitaLens
Description: Subjects between the ages of 18-69 will be randomized to 1 of 3 lenses. Solutions will be administered contralaterally with 1 test solution and 1 of 2 control solutions prior to the subjects' follow-up visits.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: RevitaLens : Clear Care/ Opti-Free : RevitaLens
Description: Subjects between the ages of 18-69 will be randomized to 1 of 3 lenses. Solutions will be administered contralaterally with 1 test solution and 1 of 2 control solutions prior to the subjects' follow-up visits.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: RevitaLens : Clear Care / RevitaLens : Opti-Free
Description: Subjects between the ages of 18-69 will be randomized to 1 of 3 lenses. Solutions will be administered contralaterally with 1 test solution and 1 of 2 control solutions prior to the subjects' follow-up visits.